Hologic, Inc. (NASDAQ:HOLX) Stock Holdings Boosted by State of Wyoming

State of Wyoming lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 210.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 7,335 shares of the medical equipment provider's stock after acquiring an additional 4,970 shares during the period. State of Wyoming's holdings in Hologic were worth $529,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Barclays PLC grew its position in Hologic by 47.6% in the 3rd quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider's stock valued at $58,507,000 after buying an additional 231,578 shares in the last quarter. Brooklyn Investment Group grew its position in Hologic by 14.7% in the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after buying an additional 145 shares in the last quarter. UMB Bank n.a. grew its position in Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after buying an additional 188 shares in the last quarter. LaFleur & Godfrey LLC grew its position in Hologic by 2.9% in the 4th quarter. LaFleur & Godfrey LLC now owns 130,373 shares of the medical equipment provider's stock valued at $9,399,000 after buying an additional 3,655 shares in the last quarter. Finally, Atwood & Palmer Inc. grew its position in Hologic by 0.5% in the 4th quarter. Atwood & Palmer Inc. now owns 357,735 shares of the medical equipment provider's stock valued at $25,789,000 after buying an additional 1,714 shares in the last quarter. Institutional investors own 94.73% of the company's stock.

Hologic Price Performance

HOLX stock opened at $56.43 on Tuesday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67. The firm has a market capitalization of $12.58 billion, a PE ratio of 17.80, a P/E/G ratio of 2.14 and a beta of 0.54. The firm has a 50-day moving average of $58.67 and a two-hundred day moving average of $67.14.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. During the same period in the prior year, the firm earned $1.03 earnings per share. The business's quarterly revenue was down 1.2% on a year-over-year basis. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of recent analyst reports. Royal Bank of Canada decreased their target price on shares of Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a research report on Friday, May 2nd. Citigroup decreased their target price on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Stephens reduced their price objective on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a research report on Tuesday, May 13th. William Blair restated an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Finally, Leerink Partners lowered shares of Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the company from $80.00 to $75.00 in a research report on Thursday, February 6th. Twelve investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Hologic has a consensus rating of "Hold" and an average target price of $77.42.

Insider Transactions at Hologic

In related news, Director Martin D. Madaus purchased 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average cost of $55.24 per share, with a total value of $300,781.80. Following the completion of the transaction, the director now directly owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.88% of the stock is owned by insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.